| Literature DB >> 25591826 |
Dionysios Papadatos-Pastos1, Roy Rabbie1, Paul Ross1, Debashis Sarker2.
Abstract
In the last decade treatment for colorectal cancer (CRC) has evolved with the addition of contemporary chemotherapy drugs and targeted therapies. Despite this progress, our drug armamentarium is by no means complete and modern molecular biology techniques have led to the identification of a number of 'druggable' targets. One of the most important current drug targets is the phosphatidyl-inositol 3-kinase (PI3K) pathway, which is frequently deregulated in patients with CRC. In vitro and in vivo data strongly support the clinical development of compounds affecting signal transduction via the PI3K pathway. In this review we outline the role of PI3K in the development and progression of CRC and discuss data from current and ongoing clinical trials targeting this pathway. In addition we make suggestions toward the optimization of future research in order to derive the maximum benefit for patients with CRC.Entities:
Keywords: Biomarkers; Colorectal; PI3K; PIK3CA; Predictive
Mesh：
Substances：
Year: 2014 PMID： 25591826 DOI： 10.1016/j.critrevonc.2014.12.006
Source DB: PubMed Journal: Crit Rev Oncol Hematol ISSN： 1040-8428 Impact factor: 6.312